樟芝是台灣特有的真菌，被認為具有保護肝臟的功能。在本試驗中，評估樟芝菌絲體發酵全液凍乾粉對硫代乙酪胺所誘導大鼠肝臟纖維化的效果。大鼠肝臟纖維化的誘導在於每週三次的腹腔注射TAA並持續8週，各組再分別給予0.5% CMC和樟芝菌絲體發酵全液凍乾粉。。試驗結果顯示，樟芝菌絲體發酵全液凍乾粉對第一、三、六和第八週TAA誘導所提高的血漿ALT和AST值有明顯降低作用，可增加第八週血清白蛋白含量及降低y-GT活性，可明顯降低脾臟重量和肝臟膠原蛋白含量，及增加肝臟蛋白質含量，並能i曾 2日glutathione含量及glutathione peroxidase的活性及減少脂質過氧化程度。而在肝臟病理切片檢查，樟芝菌絲體 發酵全液凍乾粉能抑制肝臟結節及膽管纖維化的產生。T-PCPCR分析，樟芝降低肝臟methione adenosyltransferase2A.collagen （αl)(I）、tissue inhibitor of metallopeptidase1、CD14及TNF －α的表現.另外，樟芝能降低前癌肝臟的指標，重Jy-glutamyl甘anspeptidase活性及glutathione transferase (GST)-M 、GST-Placental form的基因表現。由這些結 果可以明確的顯示，樟芝菌絲體發酵全液凍乾粉可以延緩TAA誘導大鼠肝臟纖維化及前癌肝臟的產生，對於 預防肝臟纖維化及肝癌有其發展的潛力。

Antrod/a c/nnamomea (Syn. Antrod/a camphorata and Ta/wanofungus camphorata), an endemic fungus in Taiwan, is considered an ideal liver protectant. This study aimed to investigate the protective effects of freeze-dried powder of A. c/nnamomea mycelia from submerged fermentation on thioacetamide-induced liver fibrosis in rats. Groups of male rats were treated with TAA administrated intraperitoneally at doses of 100-200 mg/kg three times per week for 8 weeks and simultaneously were given a daily oral dose of 0.5% carboxyl methyl cellulose and A. c/nnamomea mycelium (131，393 mg/kg). Experimental results showed that A. c/nnamomea mycelia significantly reduced the TAA-induced serum levels of ALT and AST at week 1，3, 6 and 8. In addition, A. c/nnamomea mycelia increased the TAA-reduced albumin levels, lowered the TAA-induced y-GT activities, decreased the TAA-induced spleen weight and liver collagen contents, augmented the TAA-deduced liver protein productions, raised the glutathione content and glutathione peroxidase activity and lessened lipid peroxidation. In the liver pathological examination, A. c/nnamomea mycelia can inhibit liver nodules and bile duct fibrosis production. RT-PCR analysis showed that A. cinnamomea mycelia treatment decreased the expression of genes encoding methione adenosyltransferase 2A, collagen (a1)(I), tissue inhibitor of metallopeptidase 1, CD14 and TNF-a. Furthermore, A. cinnamomea mycelia can reduce the biomarkers for preneoplastic liver, such as y-glutamyltranspeptidase activities and expression of genes encoding glutathione transferase (GST)-M, and GST-P. In conclusion, the present study has demonstrated that A. cinnamomea mycelia retard the progression of liver fibrosis and preneoplastic liver in TAA-treated rats. It may be expected that A. cinnamomea mycelia has potential to prevent liver fibrosis and hepatoma.